Target intelligence / Profile preview

Oxacillinase-48 β-lactamase (OXA-48) (OXA-48)

Target
OXA-48
Molecular classification
Enzyme, Beta-lactamase, Ambler Class D beta-lactamase, Serine beta-lactamase, Carbapenemase
01

Overview

Oxacillinase-48 β-lactamase (OXA-48) is a prominent Ambler Class D carbapenemase that mediates high-level resistance to penicillins and low-level resistance to carbapenems in Gram-negative bacteria [1, 6]. Primarily found in Enterobacteriaceae such as Klebsiella pneumoniae and Escherichia coli, it functions as a serine-based enzyme that hydrolyzes the β-lactam ring of antibiotics, thereby neutralizing their antibacterial activity [5, 8]. The enzyme is particularly clinically significant due to its rapid dissemination via highly mobile IncL plasmids and its ability to evade detection in routine phenotypic susceptibility tests [1, 6, 11]. While it does not naturally hydrolyze expanded-spectrum cephalosporins, it is frequently co-produced with extended-spectrum β-lactamases (ESBLs), leading to multidrug-resistant phenotypes [1, 11]. Therapeutic management of OXA-48-producing infections often relies on the use of next-generation β-lactamase inhibitors like avibactam, which covalently inactivates the enzyme to restore the efficacy of partner antibiotics [2, 4, 6]. The global spread of OXA-48 represents a major public health challenge, necessitating robust molecular surveillance and the development of novel inhibitory agents [6, 10].

Other names
OXA-48 carbapenemaseClass D carbapenemaseCarbapenem-hydrolyzing class D beta-lactamaseCHDLBeta-lactamase OXA-48OXA-48-like carbapenemaseOXA-48-like enzyme
02

Mechanism of action

Covalent inhibition of the active-site serine residue (Ser-70) to prevent antibiotic hydrolysis [8, 9]

03

Biological functions

Hydrolysis of beta-lactam antibioticsAntibiotic resistanceBacterial survival in the presence of beta-lactams
04

Disease associations

InfectionCarbapenem-resistant Enterobacteriaceae (CRE) infectionNosocomial infectionUrinary tract infectionSepsis
05

Safety considerations

Limited therapeutic optionsRapid plasmid-mediated disseminationDiagnostic challenges due to low-level carbapenem resistanceCo-production with other resistance determinants
06

Interacting drugs

Avibactam

8 more in the full profile.

07

Biomarkers

blaOXA-48 geneCarbapenem resistanceOXA-48 protein expression

Beyond the preview

Go deeper on Oxacillinase-48 β-lactamase (OXA-48) (OXA-48).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oxacillinase-48 β-lactamase (OXA-48) (OXA-48).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call